Campbell & CO Investment Adviser LLC Invests $86,000 in Global Cord Blood Corp (NYSE:CO)

Campbell & CO Investment Adviser LLC bought a new position in shares of Global Cord Blood Corp (NYSE:CO) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 17,699 shares of the medical research company’s stock, valued at approximately $86,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Man Group plc grew its stake in shares of Global Cord Blood by 28.6% during the second quarter. Man Group plc now owns 899,641 shares of the medical research company’s stock worth $5,200,000 after purchasing an additional 200,000 shares during the period. Renaissance Technologies LLC grew its stake in shares of Global Cord Blood by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,826,896 shares of the medical research company’s stock worth $16,339,000 after purchasing an additional 29,396 shares during the period. SG Americas Securities LLC grew its stake in shares of Global Cord Blood by 24.4% during the second quarter. SG Americas Securities LLC now owns 134,310 shares of the medical research company’s stock worth $776,000 after purchasing an additional 26,379 shares during the period. Parametric Portfolio Associates LLC grew its stake in shares of Global Cord Blood by 20.3% during the second quarter. Parametric Portfolio Associates LLC now owns 94,469 shares of the medical research company’s stock worth $546,000 after purchasing an additional 15,934 shares during the period. Finally, Quinn Opportunity Partners LLC grew its stake in shares of Global Cord Blood by 2.3% during the second quarter. Quinn Opportunity Partners LLC now owns 259,764 shares of the medical research company’s stock worth $1,501,000 after purchasing an additional 5,800 shares during the period. Institutional investors own 16.99% of the company’s stock.

Shares of Global Cord Blood stock opened at $5.57 on Wednesday. Global Cord Blood Corp has a 12 month low of $4.14 and a 12 month high of $7.73. The business has a fifty day simple moving average of $4.73 and a 200 day simple moving average of $5.78. The stock has a market cap of $685.54 million, a PE ratio of 13.56 and a beta of 0.14.

Global Cord Blood (NYSE:CO) last posted its earnings results on Tuesday, August 27th. The medical research company reported $0.13 earnings per share (EPS) for the quarter. Global Cord Blood had a return on equity of 9.60% and a net margin of 31.78%. The firm had revenue of $39.82 million during the quarter.

A number of equities research analysts recently commented on CO shares. ValuEngine raised Global Cord Blood from a “hold” rating to a “buy” rating in a research note on Saturday, October 5th. TheStreet cut Global Cord Blood from a “b-” rating to a “c+” rating in a research note on Wednesday, September 4th.

Global Cord Blood Profile

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

Read More: What is Call Option Volume?

Want to see what other hedge funds are holding CO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Cord Blood Corp (NYSE:CO).

Institutional Ownership by Quarter for Global Cord Blood (NYSE:CO)

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.